公开(公告)号：US20210277069A1

公开(公告)日：2021-09-09

申请号：US17265610

申请日：2019-08-09

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Maria SCARSELLI ,  Daniele VEGGI

IPC分类号： C07K14/22 ,  A61K39/095 ,  A61P31/04

摘要： The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.

公开(公告)号：US11110160B2

公开(公告)日：2021-09-07

申请号：US16774309

申请日：2020-01-28

申请人： PFIZER INC.

发明人： Jianxin Gu ,  Jin-hwan Kim ,  Avvari Krishna Prasad ,  Yu-ying Yang

IPC分类号： A61K39/095 ,  A61K47/64 ,  A61K39/09 ,  A61K45/06 ,  A61K39/00

摘要： The invention provides eTEC linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (eTEC) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.

公开(公告)号：US20210253647A1

公开(公告)日：2021-08-19

申请号：US17245681

申请日：2021-04-30

申请人： GLAXOSMITHKLINE BIOLOGICALS SA

发明人： Matthew BOTTOMLEY ,  Enrico MALITO ,  Manuele MARTINELLI ,  Maria Scarselli

IPC分类号： C07K14/22 ,  A61K39/095

摘要： Modified meningococcal fHbp polypeptides with increased stability.

公开(公告)号：US20210213129A1

公开(公告)日：2021-07-15

申请号：US17216819

申请日：2021-03-30

申请人： Immugen Pharma LLC

发明人： Craig Travis

IPC分类号： A61K39/39 ,  A61K39/04 ,  A61K39/02 ,  A61K39/05 ,  A61K39/118 ,  A61K39/085 ,  A61K39/095 ,  A61K39/08 ,  A61K39/104 ,  A61K39/112 ,  A61K39/29 ,  A61K39/225 ,  A61K39/215 ,  A61K39/145 ,  A61K39/13 ,  A61K39/165 ,  A61K39/20 ,  A61K39/205 ,  A61K39/25 ,  A61K39/00 ,  A61K39/015 ,  A61K39/008 ,  A61K39/005 ,  A61K39/002 ,  A61K39/012

摘要： Disclosed are methods and compositions related to the use cannabinoids as adjuvants for the accelerated induction and production of an antibody based immune response.

公开(公告)号：US11013799B2

公开(公告)日：2021-05-25

申请号：US15310055

申请日：2015-05-08

申请人： KANVAX BIOPHARMACEUTICALS LTD

发明人： Jianping Li

IPC分类号： A61K39/385 ,  A61K39/09 ,  A61K39/095 ,  A61K39/102 ,  A61K39/39 ,  A61K39/00

摘要： The present invention provides compositions and methods for enhancing immunogenicity of polysaccharide antigens. Immunogenic compositions and vaccines comprising polysaccharide-protein conjugates comprising a chimeric carrier protein having a universal epitope are provided. Methods of preparing the compositions, and methods for treating or preventing bacterial infections are further provided. The compositions and methods are useful for enhancing immune response in young children, elderly and immunocompromised individuals.

公开(公告)号：US10995122B2

公开(公告)日：2021-05-04

申请号：US16600282

申请日：2019-10-11

申请人： Children's Hospital & Research Center at Oakland

发明人： Peter T. Beernink

IPC分类号： A61K39/095 ,  C07K14/22 ,  A61K39/00

摘要： Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.

公开(公告)号：US20210101943A1

公开(公告)日：2021-04-08

申请号：US17126712

申请日：2020-12-18

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： C07K14/22 ,  A61K39/13 ,  A61K39/295 ,  A61K39/00 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US10967045B2

公开(公告)日：2021-04-06

申请号：US12758315

申请日：2010-04-12

申请人： Andrew Robinson ,  Margaret Robinson ,  Andrew Richard Gorringe ,  Michael John Hudson ,  Karen Margaret Reddin

发明人： Andrew Robinson ,  Andrew Richard Gorringe ,  Michael John Hudson ,  Karen Margaret Reddin

IPC分类号： A61K39/095 ,  C07K14/22 ,  A61K35/74 ,  A61K38/16 ,  A61K39/00

摘要： A composition is provided comprising N. meningitidis outer membrane vesicles, wherein said outer membrane vesicles are enriched with at least one antigenic component. The composition is suitable for use in vaccines and for treatment of infection, particularly meningococcal infection, demonstrating a broad spectrum of protection. A number of preferred antigenic components are described and include antigenic proteins and proteoglycans derived from N. meningitidis.

公开(公告)号：US20210024589A1

公开(公告)日：2021-01-28

申请号：US17060067

申请日：2020-09-30

申请人： PFIZER INC.

发明人： Annaliesa Sybil Anderson ,  Susan Kay Hoiseth ,  Kathrin Ute Jansen ,  Justin Keith Moran ,  Mark Edward Ruppen

IPC分类号： C07K14/22 ,  A61K39/095

摘要： In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.

公开(公告)号：US10786558B2

公开(公告)日：2020-09-29

申请号：US16017542

申请日：2018-06-25

申请人： THE CORPORATION OF MERCER UNIVERSITY

发明人： Martin J. D'Souza

IPC分类号： A61K39/00 ,  A61K39/155 ,  C12N7/00 ,  A61K39/165 ,  A61K39/095 ,  A61K9/00 ,  A61K9/51 ,  A61K31/245 ,  A61K31/46 ,  A61K31/5383 ,  A61K31/7036 ,  A61K31/7048 ,  A61K31/7088 ,  A61K31/727 ,  C12N15/88 ,  A61K9/16 ,  C12N5/071 ,  A61K48/00

摘要： A method for forming microspheres containing bioactive material, comprising dissolving a polymer matrix, such as albumin or beta-cyclodextrin, in an aqueous medium in a first vessel; contacting the dissolved polymer matrix with a crosslinking agent, such as glutaraldehyde, to crosslink the polymer matrix and the crosslinking agent; neutralizing with sodium bisulfate any excess crosslinking agent remaining after crosslinking is substantially complete; solubilizing in a second vessel a bioactive material in an aqueous solution; mixing the solubilized bioactive material together with the neutralized crosslinked polymer matrix in solution to form a mixture; and, spray drying the mixture to produce nanospheres, whereby substantial bioactivity of the biomaterial is retained upon cellular uptake.